IOVA stock news · Iovance Biotherapeutics, Inc.
Get alerts for IOVA
Follow Iovance Biotherapeutics, Inc. (IOVA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IOVAIovance Biotherapeutics, Inc. shares news about its lung cancer treatment trial.
NeutralIovance announced updated results from a lung cancer trial and a treatment-selection plan. The filing text gives no findings, so it does not change the company's outlook.
Today, big investors are making moves with 10 health care stocks.
NeutralIovance's call trade was labeled bearish. The report describes options activity but gives no new company result or plan, so its outlook is unchanged.
Iovance Biotherapeutics shared news about its company updates for healthcare events and investors.
NeutralIovance updated its corporate presentation for conferences and other audiences. The filing gives no new business results or plans, so it does not change the company's outlook.
Iovance Biotherapeutics shares stopped rising after reaching a new high for the year. What’s happening?
Good for IOVAIovance raised its 2026 sales forecast as demand for Amtagvi continued and its treatment-center network grew, supporting a stronger business outlook.
Big trades in 10 health care stocks happened today.
NeutralIovance had a call trade labeled bearish. This reports trader activity, not a change in Iovance's business, so it does not change its outlook.
On Tuesday, 12 health care stocks saw big price changes during the day.
NeutralIovance Biotherapeutics' shares rose 36.71%, but the story gives no business reason for the move. It reports no new company fact, so its outlook is unchanged.
CarMax reported strong earnings for the second quarter, and its stock, along with others like Iovance Biotherapeutics, went up on Tuesday.
Good for IOVAIovance raised its FY26 sales forecast. That points to expected sales above its earlier plan, supporting a more favorable outlook.
12 health care stocks are changing a lot before the market opens on Tuesday.
NeutralIovance Biotherapeutics was listed among pre-market gainers. The article gives no company news explaining the move, so it does not change the view of its business.
Iovance Biotherapeutics, Inc. shares news about its money plans for 2026.
NeutralIovance reported an update to its full-year 2026 revenue forecast, but gave no figures or direction in this filing. The report alone does not change its outlook.
Iovance (IOVA) shares jump following Q2 results that surpassed forecasts.
NeutralIovance Biotherapeutics shares surged after the company reported Q2 results that exceeded expectations, with a notable revenue increase and a potential upward revision of full-year guidance. This strong performance reflects growing demand for its FDA-approved cancer therapy, Amtagvi, and positions the company favorably in the market.